溶血磷脂酸、人附睾蛋白4检测对卵巢癌的早期诊断价值

摘要

目的 探讨溶血磷脂酸(LPA)、人附睾蛋白4(HE4)检测对卵巢癌早期诊断的价值.方法 测定121例女性血清样品,其中早期卵巢癌组31例,非恶性卵巢疾病组40例,健康体检女性50例,用定磷法、ELISA法分别检测血清LPA、HE4含量.结果 LPA、HE4含量在早期卵巢癌组分别为(12.24±6.16)μ mol/L、(102.8±167.3)pmol/L,均明显高于非恶性卵巢疾病组(2.32±1.03)μmol/L、(34.3±12.1)pmol/L和健康体检组(2.04±0.68)μ mol/L、(28.6±8.3)pmol/L,两组比较有极显著性差异(P＜0.01).作为早期卵巢癌的实验诊断,LPA、HE4联合检测优于单项检测,其敏感性为96.8%、特异性为87.8%,准确度为90.1%.结论 LPA、HE4检测在卵巢癌的早期诊断具有重要的临床应用价值,二者联合检测更有利于卵巢癌的早期诊断.%Objective To explore the specific value of lysophosphatidic acid (LPA) and human epididymis protein 4 ( HE4 ) on the early diagnosis of ovarian cancer. Methods Among the 121female patients serum samples colleted from the local hospital, 31 cases are early ovarian cancer group, 40cases are the nonmalignant ovarian disease group, 50 cases are the healthy check-up female. By means of phosphorus and ELISA,We can analyse the content of LPA and HE4 in serum .Results The value of LPA and HE4 In early-stage ovarian cancer group are( 12.24 ± 6.16) μ mol/L and(102.8 ± 167.3)pmol/L,respectively, much higher than the nonmalignant ovarian disease' s(2.32 ± 1.03) μ mol/L、(34.3 ± 12.1)pmol/L and the health check-up' s(2.04 ± 0.68)μ mol/L、(28.6 ± 8.3)pmol/L, Significant difference (P＜ 0.01). As the early experimental diagnoses for ovarian cancer, the conbination test of LPA and HE4 is better than the any single test of them. The conbination test' s sensitivity is 96.8%, its specificity is 87.8%,its accuracy is 90.1%. Conclusion Detect the LPA and HE4 in the early diagnosis of ovarian cancer has important value for clinical applications, It' s superior than the single use for early diagnosis in ovarian cancer.